Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, randomized, double-blind, single ascending-dose study of ADG20 in healthy adult participants

Next Previous
Trial Profile

A Phase 1, randomized, double-blind, single ascending-dose study of ADG20 in healthy adult participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adintrevimab (Primary) ; Adintrevimab (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man
  • Sponsors Invivyd

Most Recent Events

  • 12 Oct 2022 According to an Invivyd media release, preliminary results from the trial will be presented at the ID Week 2022.
  • 12 Sep 2022 According to an Adagio Therapeutics media release, Adagio Therapeutics has changed its name to Invivyd.
  • 05 May 2021 According to an Adagio Therapeutics media release, blinded data from this study supports the initiation of the Phase 2/3 EVADE trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top